{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:33Z","timestamp":1747207353150,"version":"3.40.5"},"reference-count":11,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:sec>\n<jats:title>Introduction::<\/jats:title>\n<jats:p>Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by a high\nrisk of recurrence after radical resection. The role of adjuvant systemic therapy in radically resected\npatients is unclear. Mitotane, a steroidogenesis inhibitor, is the only drug approved for the systemic\ntreatment of advanced ACC. In 2007, a retrospective case-control study provided the evidence that\nmitotane, administered for two years after successful surgery, could prolong recurrence-free survival.\nAdrenal insufficiency (AI), which occurs in almost all patients during the first 12 months of treatment,\nis an expected side effect of mitotane and requires steroid replacement therapy. Due to its long halflife,\nmitotane-induced AI persists several months after treatment discontinuation and is managed by\ncautious tapering of glucocorticoid replacement therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results::<\/jats:title>\n<jats:p>We report a case of symptomatic AI diagnosed after a severe allergic reaction occurring three\nyears after the discontinuation of adjuvant mitotane therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions::<\/jats:title>\n<jats:p>The case suggests that mitotane-induced AI should be monitored for a long time to asses\nfull recovery of adrenal function, in order to prevent adrenal crises.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871530319666190809144620","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T05:50:46Z","timestamp":1568181046000},"page":"485-487","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4443-0232","authenticated-orcid":true,"given":"Leonardo","family":"Muratori","sequence":"first","affiliation":[{"name":"Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pia","sequence":"additional","affiliation":[{"name":"Internal Medicine and Endocrinology Unit, Department of Clinical and Biological Sciences, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Reimondo","sequence":"additional","affiliation":[{"name":"Internal Medicine and Endocrinology Unit, Department of Clinical and Biological Sciences, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pisano","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"La Salvia","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Oncology, Hospital Universitario 12 de Octubre, Avenida Cordoba, s\/n, 28041 Madrid, Spagna, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Internal Medicine and Endocrinology Unit, Department of Clinical and Biological Sciences, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Sperone","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"first-page":"914","year":"2001","key":"ref=1","unstructured":"Dackiw, Alan PB, et al. \"Adrenal cortical carcinoma.\" World journal of surgery 25.7. 2001,914"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10434-999-0719-7","volume":"6","author":"Schulick R.D.","year":"1999","unstructured":"Schulick R.D.; Brennan M.F.; Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999,6(8),719-726","journal-title":"Ann Surg Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","volume":"27.27","author":"Veytsman Irina","year":"2009","unstructured":"Veytsman Irina; Nieman Lynnette; Fojo Tito;  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinomaJournal of clinical oncology 2009,27.27,4619","journal-title":"Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinomaJournal of clinical oncology"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0608","author":"Fassnacht Martin","year":"2018","unstructured":"Fassnacht Martin; European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European journal of endocrinology 1aop 2018","journal-title":"European journal of endocrinology 1aop"},{"key":"ref=5","first-page":"9","volume":"37","author":"De Francia S.","year":"2012","unstructured":"De Francia S.; Ardito A.; Daffara F.; Zaggia B.; Germano A.; Berruti A.; Di Carlo F.; Mitotane treatment for adrenocortical carcinoma: an overview. Minerva Endocrinol 2012,37(1),9-23","journal-title":"Minerva Endocrinol"},{"key":"ref=6","first-page":"127","volume":"43","author":"Michalakis K.","year":"2009","unstructured":"Michalakis K.; Ilias I.; Medical management of adrenal disease: a narrative review. Endocr Regul 2009,43(3),127-135","journal-title":"Endocr Regul"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"Reidy-Lagunes D.L.","year":"2017","unstructured":"Reidy-Lagunes D.L.; Lung B.; Untch B.R.; Raj N.; Hrabovsky A.; Kelly C.; Gerst S.; Katz S.; Kampel L.; Chou J.; Gopalan A.; Saltz L.B.; Complete responses to mitotane in metastatic adrenocortical carcinoma\u2014A new look at an old drug. Oncologist 2017,22(9),1102-1106","journal-title":"Oncologist"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"Terzolo M.","year":"2007","unstructured":"Terzolo M.; Angeli A.; Fassnacht M.; Daffara F.; Tauchmanova L.; Conton P.A.; Rossetto R.; Buci L.; Sperone P.; Grossrubatscher E.; Reimondo G.; Bollito E.; Papotti M.; Saeger W.; Hahner S.; Koschker A.C.; Arvat E.; Ambrosi B.; Loli P.; Lombardi G.; Mannelli M.; Bruzzi P.; Mantero F.; Allolio B.; Dogliotti L.; Berruti A.; Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007,356(23),2372-2380","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1002\/1097-0142(197811)42:5<2177:AID-CNCR2820420514>3.0.CO;2-X","volume":"42","author":"Hogan T.F.","year":"1978","unstructured":"Hogan T.F.; Citrin D.L.; Johnson B.M.; Nakamura S.; Davis T.E.; Borden E.C.; o,p\u2032-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 1978,42(5),2177-2181","journal-title":"Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF00258213","volume":"7","author":"Moolenaar A.J.","year":"1981","unstructured":"Moolenaar A.J.; van Slooten H.; van Seters A.P.; Smeenk D.; Blood levels of o,p\u2032-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol 1981,7(1),51-54","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1530\/EJE-17-0452","volume":"177","author":"Reimondo G.","year":"2017","unstructured":"Reimondo G.; Puglisi S.; Zaggia B.; Basile V.; Saba L.; Perotti P.; De Francia S.; Volante M.; Zatelli M.C.; Cannav\u00f2 S.; Terzolo M.; Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. Eur J Endocrinol 2017,177(4),361-367","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T03:22:17Z","timestamp":1586834537000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174238\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530319666190809144620","relation":{},"ISSN":["1871-5303"],"issn-type":[{"type":"print","value":"1871-5303"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}